Delta-10 THC
Delta-10-Tetrahydrocannabinol
Delta-10-THC is a minor THC isomer that occurs in cannabis at trace levels and is primarily produced synthetically from CBD for commercial markets. It is reported to produce milder, more stimulating psychoactive effects than Delta-9-THC. Research is extremely limited, and safety data on commercial products is a significant concern.
Mildly psychoactive — reported to be less potent than Delta-9-THC with more stimulating, energizing effects. Precise CB1 binding affinity data is limited. Higher doses may produce effects comparable to Delta-9-THC.
Quick Facts
- Molecular Formula
- C₂₁H₃₀O₂
- Molecular Weight
- 314.46 g/mol
- Boiling Point
- ~175°C (347°F) — estimated
- Legal Status (U.S.)
- Same contested federal status as Delta-8-THC
- Research Status
- Extremely limited
About Delta-10 THC
Delta-10-tetrahydrocannabinol (Δ10-THC) is a structural isomer of Delta-9-THC with the double bond at the 10th carbon position of the cyclohexene ring. It was first identified in cannabis in trace amounts and gained commercial attention after the 2018 Farm Bill created a market for hemp-derived cannabinoids.
The origin story of commercial Delta-10 is notable: it was reportedly discovered accidentally by a California cannabis company (Fusion Farms) in 2020 when fire retardant-contaminated cannabis produced an unusual crystalline substance that was eventually identified as Delta-10-THC. This underscores the synthetic nature of commercial Delta-10 — it is not meaningfully present in natural cannabis and is produced via chemical isomerization of CBD, the same process used for Delta-8-THC.
Pharmacologically, Delta-10-THC is believed to bind CB1 receptors with lower affinity than both Delta-9 and Delta-8-THC, though precise binding data is limited. Users report effects described as more energizing and sativa-like compared to the more sedating Delta-8-THC — a distinction that may reflect differences in CB1 binding kinetics or the presence of synthesis byproducts rather than Delta-10 itself.
The research base for Delta-10-THC is extremely sparse. There are no published human clinical trials. Most available information comes from in vitro binding studies, animal models, or consumer reports. A 2022 review in Cannabis and Cannabinoid Research noted that Delta-10-THC had the least research of any commercially marketed cannabinoid.
Safety concerns mirror those for Delta-8-THC: commercial synthesis produces byproducts that are not well characterized. Third-party testing is inconsistent, and many products contain Delta-9-THC at levels that would make them federally illegal. The FDA has not evaluated any Delta-10 products for safety or efficacy.
Receptor Affinity
- CB1 agonist (lower affinity than Δ9-THC — precise data limited)
- CB2 agonist (presumed)
- GPR55 agonist (presumed)
Key Mechanisms
- CB1 partial agonism — psychoactive effects via endocannabinoid system, lower potency than Delta-9-THC
- CB2 agonism — presumed anti-inflammatory effects based on structural similarity to other THC isomers
- Exact pharmacological profile not well characterized due to limited research
Clinical Uses & Evidence
Graded using a modified GRADE framework. Grade A = strong evidence; B = moderate; C = preliminary.
No established clinical uses
Grade CNo human clinical trials have been conducted for Delta-10-THC. Any therapeutic claims are extrapolated from structural similarity to Delta-9-THC or from anecdotal reports.
Side Effects
Drug Interactions
Additive CNS effects via CB1 agonism
Reported stimulating effects of Delta-10 may be additive
Presumed CYP3A4 metabolism based on structural similarity to Delta-9-THC
Always consult a pharmacist or physician before combining cannabis with prescription medications. This list is not exhaustive.
Dosing Notes
No established dosing. Extremely limited safety data. Commercial products vary widely in potency and purity. Synthesis byproducts are a significant unknown risk. Only use products with comprehensive third-party COA testing from ISO-accredited labs. Not recommended for individuals with cardiovascular conditions, psychiatric history, pregnancy, or those taking medications. The stimulating effects reported by users may reflect product impurities rather than Delta-10-THC itself.
Dosing information is for educational purposes only. Consult a licensed healthcare provider for personalized guidance.
Legal Status
Same contested federal status as Delta-8-THC. DEA's 2020 Interim Final Rule classifies synthetically derived THC isomers as Schedule I. State laws vary — some states have explicitly banned Delta-10 alongside Delta-8. Legal status is rapidly evolving. Verify current state and federal regulations before use or sale.
Key Sources
- Delta-8-THC, Delta-10-THC, and other minor cannabinoids: a review. Cannabis and Cannabinoid Research, 2022.
- Pharmacology of cannabinoid CB1 and CB2 receptors. Pharmacology & Therapeutics, 1997.
- Emerging cannabinoids: a review of the evidence. Journal of Cannabis Research, 2023.